title: Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
abstract: BACKGROUND
  Dalfampridine extended release 10mg tablets (D-ER) have demonstrated improvement in walking for ambulatory persons with multiple sclerosis (pwMS), termed "responders."
  
  
  OBJECTIVE
  This study examined the extent additional aspects of gait and dexterity change for patients prescribed D-ER.
  
  
  METHODS
  Over 14-weeks, walking endurance, dynamic gait, self-report walking ability and fine and gross dexterity were examined in pwMS prescribed D-ER as a part of routine clinical care.
  
  
  RESULTS
  The final results (n=39) validate that a subset of pwMS improve walking speed (Time 25-Foot Walk Test, p<0.0001). Significant improvements in gait and dexterity were observed even among participants who did not improve walking speed. Improvements were evident in gait and dexterity domains including Six Minute Walk Test, p=0.007, Six-Spot Step Test, p<0.0001, Multiple Sclerosis Walking Scale-12, p<0.0001, Nine Hole Peg Test, p<0.0001 dominant and non-dominant sides, and Box and Blocks Test, p=0.005 and 0.002, dominant and non-dominant sides, respectively.
  
  
  CONCLUSIONS
  These findings suggest that D-ER may be a potential treatment for gait impairments, beyond walking speed and dexterity in pwMS. Further investigation regarding D-ER response is warranted.
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA; Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA; Department of Neurology, Brown University, Providence, RI, USA. Electronic address: Albert_Lo@brown.edu.
authors.forename: A C
authors.initials: AC
authors.lastname: Lo
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Ruiz
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Koenig
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Anderson
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Olson
authors.affiliation: Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT, USA; Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA.
authors.forename: E W
authors.initials: EW
authors.lastname: Triche
mesh_terms: D015761:4-Aminopyridine / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D016503:Drug Delivery Systems; D005080:Exercise Test; D005260:Female; D020233:Gait Disorders, Neurologic / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D011446:Prospective Studies; D011930:Reaction Time; D057566:Self Report; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D016138:Walking / Q000502:physiology
chemical_list: D026902:Potassium Channel Blockers; D015761:4-Aminopyridine
keywords: Dalfampridine; Dexterity; Gait; Multiple Sclerosis; Walking